{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:04:28Z","timestamp":1783699468948,"version":"3.55.0"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,2,21]]},"abstract":"<jats:p>\n            Eravacycline is a novel, fully synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by resistant Gram-positive pathogens. Here, we evaluated the\n            <jats:italic>in vitro<\/jats:italic>\n            activities of eravacycline and comparator antimicrobial agents against a recent global collection of frequently encountered clinical isolates of Gram-positive bacteria. The CLSI broth microdilution method was used to determine\n            <jats:italic>in vitro<\/jats:italic>\n            MIC data for isolates of\n            <jats:italic>Enterococcus<\/jats:italic>\n            spp.\n          <\/jats:p>","DOI":"10.1128\/aac.01715-19","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T12:59:35Z","timestamp":1576501175000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["<i>In Vitro<\/i>\n            Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017"],"prefix":"10.1128","volume":"64","author":[{"given":"Ian","family":"Morrissey","sequence":"first","affiliation":[{"name":"IHMA Europe S\u00e0rl, Monthey, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hawser","sequence":"additional","affiliation":[{"name":"IHMA Europe S\u00e0rl, Monthey, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle H.","family":"Lob","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Department of Medicine, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Ralph","family":"Corey","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Olesky","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Newman","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Fyfe","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States 2013. Centers for Disease Control and Prevention Atlanta GA. https:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2016.1204911"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0545-8"},{"key":"e_1_3_3_6_2","unstructured":"Reference deleted."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00366-16"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04354-14"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm201465w"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06187-11"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01288-13"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04809-14"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02403-15"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.965253"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx147"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.12.013"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.11.024"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.01.022"},{"key":"e_1_3_3_19_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th ed. Approved standard M07-A11. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_3_20_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing, 29th ed. M100. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"29"},{"key":"e_1_3_3_21_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for interpretation of MICs and zone diameters version 9.0. http:\/\/www.eucast.org."},{"key":"e_1_3_3_22_2","volume-title":"Tygacil (tigecycline)\u2014tigecycline injection, powder, lyophilized, for solution prescribing information","author":"Wyeth Pharmaceuticals Inc","year":"2016","unstructured":"Wyeth Pharmaceuticals Inc. 2016. Tygacil (tigecycline)\u2014tigecycline injection, powder, lyophilized, for solution prescribing information. Wyeth Pharmaceuticals Inc, Philadelphia, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01715-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01715-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:48:27Z","timestamp":1645480107000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01715-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2,21]]}},"alternative-id":["10.1128\/AAC.01715-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.01715-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"assertion":[{"value":"2019-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01715-19"}}